Skip to main content
Caplight Logo









Neela Cell Therapeutics

Neela Cell Therapeutics

Private
Athens, GeorgiaHealthcare & Life Scienceshttps://neelacelltx.com/

Last Round

Convertible Debt

Nov 24, 2025

Total Funding Raised

$13.56M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Neela Cell Therapeutics is a biotechnology company developing genipin as a treatment for peripheral neuropathy and producing peripheral neurons from human pluripotent stem cells for research.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

peripheral neuropathygenipinperipheral neuronsnerve regenerationhuman pluripotent stem cellshPSCdrug discovery toolsdisease-modifying treatmentstem cell linescell modelsdisease modelingneurotherapeuticsbiotechpre-clinical development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neela Cell Therapeutics Comparables

Compare Neela Cell Therapeutics with similar companies based on industry and business-model similarity.

Neela Cell Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BrainXell
78%
WinSanTor
76%
bit.bio
76%

Neela Cell Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtNov 24, 2025
GrantJun 1, 2025

Neela Cell Therapeutics Investors

Notable investors and investment history

Neela Cell Therapeutics investors
InvestorRounds
Georgia Research AllianceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 24, 2025

    $14M round led by Biogen.

  • Jun 1, 2025

    $50K grant received from Georgia Research Alliance.

Neela Cell Therapeutics Filings

Explore SEC and related filing metadata, where available.

Neela Cell Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neela Cell Therapeutics's valuation, stock price, and market status.

Is Neela Cell Therapeutics a public or private company?

Neela Cell Therapeutics is a private company.

What is the current stock price of Neela Cell Therapeutics?

Neela Cell Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Neela Cell Therapeutics worth (valuation)?

Valuation information for Neela Cell Therapeutics is not publicly available.

Can I buy Neela Cell Therapeutics stock?

Neela Cell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neela Cell Therapeutics's last funding round?

Neela Cell Therapeutics's most recent funding round was Convertible Debt on November 24, 2025.

Who are the main investors in Neela Cell Therapeutics?

Key investors in Neela Cell Therapeutics include Georgia Research Alliance.

Will Neela Cell Therapeutics IPO soon?

No public IPO plans have been announced for Neela Cell Therapeutics.

How can I track Neela Cell Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neela Cell Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAthens, Georgia
Year Founded2024
Last FundingNov 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?